Skip to main content

Advertisement

SpringerLink
Log in

Clinical use of opioids for cancer pain

  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Successful management of pain in the cancer patient requires careful assessment of the components of the pain complaint and accurate diagnosis of the cause of pain. Symptomatic management of pain involves pharmacotherapeutic strategies that focus on opioid use. Factors influencing the choice of opioid in patients with cancer pain include the severity of pain, the presence of coexisting disease, response to previous analgesic therapy, pharmacokinetic factors, available formulations, and patient compliance. Long-term opioid prescription always requires individual titration of medication to adequate pain relief, which is determined on an individual patient basis and/or based on manageable adverse effects. Failure to continuously monitor opioid use generally results in overtreatment or undertreatment of pain. The cognitive and psychomotor effects of long-term opioid therapy are not well-defined and merit further study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Practice guidelines for cancer pain management. A report by the American Society of Anesthesiologists Task Force on Pain Management, Cancer Pain Section. Anesthesiology 1996, 84:1243–1257.

    Article  Google Scholar 

  2. Bruera E, Kim HN: Cancer pain. JAMA 2003, 290:2476–2479.

    Article  PubMed  CAS  Google Scholar 

  3. Cancer Pain Relief with a Guide to Opioid Availability. Geneva, Switzerland: World Health Organization; 1996.

  4. Resnik DB, Rehm M, Minard RB: The undertreatment of pain: scientific, clinical, cultural, and philosophical factors. Med Health Care Philos 2001, 4:277–288.

    Article  PubMed  CAS  Google Scholar 

  5. Elliott TE, Murray DM, Elliott BA, et al.: Physician knowledge and attitudes about cancer pain management: a survey from the Minnesota cancer pain project. J Pain Symptom Manage 1995, 10:494–504.

    Article  PubMed  CAS  Google Scholar 

  6. Joranson DE, Gilson AM, Dahl JL, Haddox JD: Pain management, controlled substances, and state medical board policy: a decade of change. J Pain Symptom Manage 2002, 23:138–147.

    Article  PubMed  Google Scholar 

  7. Sloan PA, Plymale MA, Johnson M, et al.: Cancer pain management skills among medical students: the development of a Cancer Pain Objective Structured Clinical Examination. J Pain Symptom Manage 2001, 21:298–306.

    Article  PubMed  CAS  Google Scholar 

  8. Fitzgibbon DR, Galer BS: The efficacy of opioids in cancer pain syndromes. Pain 1994, 58:429–431.

    Article  PubMed  CAS  Google Scholar 

  9. Management of cancer pain guideline overview. Agency for Health Care Policy and Research. Rockville, Maryland. J Natl Med Assoc 1994, 86:571–573, 634.

    Google Scholar 

  10. The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain 1997, 13:6–8.

    Article  Google Scholar 

  11. Model policy for the use of controlled substances for the treatment of pain. J Pain Palliat Care Pharmacother 2005, 19:73–78.

  12. Zelman DC, Smith MY, Hoffman D, et al.: Acceptable, manageable, and tolerable days: patient daily goals for medication management of persistent pain. J Pain Symptom Manage 2004, 28:474–487.

    Article  PubMed  Google Scholar 

  13. Riley J, Ross JR, Rutter D, et al.: No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer 2006, 14:56–64.

    Article  PubMed  Google Scholar 

  14. Gaertner J, Radbruch L, Giesecke T, et al.: Assessing cognition and psychomotor function under long-term treatment with controlled release oxycodone in non-cancer pain patients. Acta Anaesthesiol Scand 2006, 50:664–672.

    Article  PubMed  CAS  Google Scholar 

  15. Ripamonti C, Dickerson ED: Strategies for the treatment of cancer pain in the new millennium. Drugs 2001, 61:955–977.

    Article  PubMed  CAS  Google Scholar 

  16. van Dorp E, Yassen A, Sarton E, et al.: Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology 2006, 105:51–57.

    Article  PubMed  Google Scholar 

  17. Hoskin PJ, Hanks GW: Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs 1991, 41:326–344.

    PubMed  CAS  Google Scholar 

  18. Uhl GR, Sora I, Wang Z: The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci U S A 1999, 96:7752–7755.

    Article  PubMed  CAS  Google Scholar 

  19. Klepstad P, Dale O, Skorpen F, et al.: Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand 2005, 49:902–908.

    Article  PubMed  CAS  Google Scholar 

  20. Flores CM, Mogil JS: The pharmacogenetics of analgesia: toward a genetically-based approach to pain management. Pharmacogenomics 2001, 2:177–194.

    Article  PubMed  CAS  Google Scholar 

  21. Chevlen E: Opioids: a review. Curr Pain Headache Rep 2003, 7:15–23.

    Article  PubMed  Google Scholar 

  22. Cherny N: New strategies in opioid therapy for cancer pain. J Oncol Manag 2000, 9:8–15.

    PubMed  CAS  Google Scholar 

  23. Cherny NI: Opioid analgesics: comparative features and prescribing guidelines. Drugs 1996, 51:713–737.

    PubMed  CAS  Google Scholar 

  24. McCarberg BH, Barkin RL: Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther 2001, 8:181–186.

    Article  PubMed  CAS  Google Scholar 

  25. Tassain V, Attal N, Fletcher D, et al.: Long term effects of oral sustained release morphine on neuropsychological performance in patients with chronic non-cancer pain. Pain 2003, 104:389–400.

    Article  PubMed  CAS  Google Scholar 

  26. Ferrell B, Wisdom C, Wenzl C, Brown J: Effects of controlled-released morphine on quality of life for cancer pain. Oncol Nurs Forum 1989, 16:521–526.

    PubMed  CAS  Google Scholar 

  27. Marcus DA, Glick RM: Sustained-release oxycodone dosing survey of chronic pain patients. Clin J Pain 2004, 20:363–366.

    Article  PubMed  Google Scholar 

  28. Levy MH: Pharmacologic treatment of cancer pain. N Engl J Med 1996, 335:1124–1132.

    Article  PubMed  CAS  Google Scholar 

  29. Hanks GW, Conno F, Cherny N, et al.: Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001, 84:587–593.

    Article  PubMed  CAS  Google Scholar 

  30. Galer BS, Coyle N, Pasternak GW, Portenoy RK: Individual variability in the response to different opioids: report of five cases. Pain 1992, 49:87–91.

    Article  PubMed  CAS  Google Scholar 

  31. Coluzzi PH: Oral patient-controlled analgesia. Semin Oncol 1997, 24(Suppl 16):S16-35–S16-42.

    Google Scholar 

  32. Pappagallo M, Dickerson ED, Hulka S: Palliative care and hospice opioid dosing guidelines with breakthrough pain (BP) doses. Am J Hosp Palliat Care 2000, 17:407–413.

    Article  PubMed  CAS  Google Scholar 

  33. Cherny N, Ripamonti C, Pereira J, et al.: Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001, 19:2542–2554.

    PubMed  CAS  Google Scholar 

  34. Eichman JD, Robinson JR: Mechanistic studies on effervescent-induced permeability enhancement. Pharm Res 1998, 15:925–930.

    Article  PubMed  CAS  Google Scholar 

  35. Darwish M, Tempero K, Kirby M, Thompson J: Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. Clin Ther 2006, 28:715–724.

    Article  PubMed  CAS  Google Scholar 

  36. Portenoy RK, Taylor D, Messina J, Tremmel L: A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006, 22:805–811.

    Article  PubMed  Google Scholar 

  37. Kochhar R, Legrand SB, Walsh D, et al.: Opioids in cancer pain: common dosing errors. Oncology (Williston Park) 2003, 17:571–575.

    Google Scholar 

  38. Janicki PK: Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit 2005, 11:RA322–RA328.

    PubMed  CAS  Google Scholar 

  39. Mercadante S, Casuccio A, Fulfaro F, et al.: Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001, 19:2898–2904.

    PubMed  CAS  Google Scholar 

  40. Indelicato RA, Portenoy RK: Opioid rotation in the management of refractory cancer pain. J Clin Oncol 2002, 20:348–352.

    PubMed  Google Scholar 

  41. Cherny NI, Portenoy RK: Cancer pain management. Current strategy. Cancer 1993, 72:3393–3415.

    Article  PubMed  CAS  Google Scholar 

  42. Jamison RN, Schein JR, Vallow S, et al.: Neuropsychological effects of long-term opioid use in chronic pain patients. J Pain Symptom Manage 2003, 26:913–921.

    Article  PubMed  Google Scholar 

  43. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS: Can patients taking opioids drive safely? A structured evidence-based review. J Pain Palliat Care Pharmacother 2002, 16:9–28.

    Article  PubMed  Google Scholar 

  44. Chapman SL, Byas-Smith MG, Reed BA: Effects of intermediate-and long-term use of opioids on cognition in patients with chronic pain. Clin J Pain 2002, 18:S83–S90.

    Article  PubMed  Google Scholar 

  45. Vainio A, Ollila J, Matikainen E, et al.: Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 1995, 346:667–670.

    Article  PubMed  CAS  Google Scholar 

  46. Galski T, Williams JB, Ehle HT: Effects of opioids on driving ability. J Pain Symptom Manage 2000, 19:200–208.

    Article  PubMed  CAS  Google Scholar 

  47. Byas-Smith MG, Chapman SL, Reed B, Cotsonis G: The effect of opioids on driving and psychomotor performance in patients with chronic pain. Clin J Pain 2005, 21:345–352.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesiology, University of Washington School of Medicine, Box 356540, 1959 NE Pacific Street, Seattle, WA, 98195, USA

    Dermot R. Fitzgibbon MD

Authors
  1. Dermot R. Fitzgibbon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dermot R. Fitzgibbon MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fitzgibbon, D.R. Clinical use of opioids for cancer pain. Current Science Inc 11, 251–258 (2007). https://doi.org/10.1007/s11916-007-0200-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11916-007-0200-x

Keywords

Search

Navigation